Address

Role of Pharmacovigilance in Successful Clinical Development
The Role of Pharmacovigilance in Successful Clinical Development

Most drugs that fail late, fail on efficacy. Safety is the next big reason. A JAMA Internal Medicine study tracked 640 novel therapeutics in late-stage trials. Of the 344 that failed, 17% failed because of safety concerns.  A Tufts CSDD analysis of 812 compounds from the top 50 drug companies found an even higher share. […]

Building an Effective Data Safety Monitoring Board
Building an Effective Data Safety Monitoring Board (DSMB): A Sponsor’s Quick-Start Guide

In July 2002, the US Women’s Health Initiative stopped its estrogen plus progestin trial about three years early. The trial had enrolled 16,608 women. Its data safety monitoring board had found that health risks exceeded the benefits, and its recommendation was unanimous.  That call protected thousands of women. It worked because the board, its stopping […]

clinical evaculation
Clinical Evaluation Reports (CER) Explained: What Class II and III Devices Actually Require

Your device has passed bench testing. The design is frozen. Then the notified body sends back a long list of questions, and most of them point at one document.  That document is the clinical evaluation report (CER). Under the EU Medical Device Regulation (MDR), it is your proof of safety, performance and clinical benefit. For […]

Post-Market Surveillance
Post-Market Surveillance: The Compliance Task Most Device Makers Underinvest In

Most device companies spend years and large budgets getting a product approved. Once the device is on the market, the team moves on to the next launch, and post market surveillance gets whatever time and money are left.  That is a costly mistake. Regulators now treat data from post market surveillance medical devices programs as […]

Clinical Trial for Your Device
Do You Need a Clinical Trial for Your Device? A Decision Framework by Risk Class

Your team might get this one wrong. For most device companies, a clinical trial is the biggest cost and the longest delay on the road to market. Some run a study they never needed. Others skip one and then get stuck in regulatory review for months.  The real question is not “trial or no trial?” […]

Patient Recruitment Strategies
How Patient Recruitment Strategies Impact Clinical Trial Timelines Patient Recruitment Strategies Impact Clinical Trial Timelines

Most clinical trials do not slip because the science fails. They slip because patients do not enrol fast enough.  According to National Library of Medicine, recruitment can take up to 30% of the drug development timeline, and delays of one to six months are common.   For pharma teams, this makes clinical trial recruitment strategies one […]

Quality Biospecimen Collection
Why Quality Biospecimen Collection Matters in Clinical Research

In clinical research, a blood draw or a tissue sample is a valuable raw data. If that sample is damaged in the first minutes after it is taken, no lab test, statistician or software tool can fix it later.  That is why biospecimen collection deserves the same careful planning as protocol design or site selection. […]

How to Design a Supplement Efficacy Study for a New Product Launch
How to Design a Supplement Efficacy Study for a New Product Launch

Imagine spending months and a six-figure budget on a supplement launch, only to watch a competitor’s bottle outsell yours because of three words on the label: “clinically proven results.”   That gap between a good product and a proven one is often what decides who wins the shelf. Supplements do not need FDA approval before they […]

First-in-Human Trials
First-in-Human Trials: What Early-Stage Biotech’s Get Wrong About Study Design

Human clinical trials are supposed to answer one simple question: does this treatment work, and is it safe? But the first time a new drug is given to a person, known as a first in human study, is where many biotech programs quietly go wrong. The problem is rarely bad luck. It is usually study […]

The Role of Biospecimens in Advancing Emerging Oncology Modalities
The Role of Biospecimens in Advancing Emerging Oncology Modalities

Introduction  The oncology landscape is undergoing a remarkable transformation. Advances in precision medicine, immunotherapy, cell and gene therapies, antibody-drug conjugates (ADCs), and targeted therapies are redefining how cancer is diagnosed, treated, and monitored. These emerging oncology modalities are enabling more personalized treatment approaches, improving patient outcomes, and accelerating the development of innovative therapeutics.  Behind these […]